OMB approves
this collection contingent upon the agency adhering to the
agreement outlined in the June 12, 1996, correspondence.
Specifically, FDA will incorporate these information collection
requirements, as revised under the National Environmental Policy
Act proposed rule (21 CFR 25.15(d) and 21 CFR 25.40(a)(c)), into
the OMB-approved package for 21 CFR Part 25 (OMB No. 0910-0190) at
the final rule stage. At that time, FDA will re-calculate the
burden for this package, as well as for the entire package.
Inventory as of this Action
Requested
Previously Approved
06/30/1999
06/30/1999
1
0
0
1
0
0
0
0
0
The Food and Drug Administration has
determined that certain classes of FDA-regulated actions have
little or no potential to cause significant environmental effects
and, therefore under this proposal, would be added to the list of
actions excluded from requirements to prepare an Environmental
Assessment or Environmental Impact Statement.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.